Caliber Wealth Management LLC Acquires 277 Shares of Stryker Co. (NYSE:SYK)

Caliber Wealth Management LLC increased its holdings in Stryker Co. (NYSE:SYKGet Rating) by 4.4% in the 2nd quarter, Holdings Channel reports. The fund owned 6,556 shares of the medical technology company’s stock after buying an additional 277 shares during the quarter. Caliber Wealth Management LLC’s holdings in Stryker were worth $1,304,000 as of its most recent SEC filing.

Other large investors also recently bought and sold shares of the company. First Western Trust Bank purchased a new position in Stryker during the first quarter valued at $1,090,886,000. Norges Bank bought a new position in Stryker in the 4th quarter worth about $816,519,000. Ontario Teachers Pension Plan Board grew its position in Stryker by 87,902.2% during the 1st quarter. Ontario Teachers Pension Plan Board now owns 2,077,732 shares of the medical technology company’s stock valued at $555,482,000 after purchasing an additional 2,075,371 shares during the last quarter. Wellington Management Group LLP increased its stake in Stryker by 11.3% during the 1st quarter. Wellington Management Group LLP now owns 15,370,391 shares of the medical technology company’s stock valued at $4,109,274,000 after purchasing an additional 1,561,376 shares in the last quarter. Finally, AustralianSuper Pty Ltd bought a new position in shares of Stryker in the first quarter worth approximately $295,397,000. 76.44% of the stock is owned by hedge funds and other institutional investors.

Stryker Stock Down 2.4 %

Shares of SYK stock opened at $221.25 on Monday. The company has a 50 day simple moving average of $211.40 and a two-hundred day simple moving average of $228.93. The stock has a market cap of $83.67 billion, a P/E ratio of 40.75, a P/E/G ratio of 2.69 and a beta of 1.03. Stryker Co. has a 12 month low of $188.84 and a 12 month high of $280.43. The company has a current ratio of 2.00, a quick ratio of 1.15 and a debt-to-equity ratio of 0.85.

Stryker (NYSE:SYKGet Rating) last announced its earnings results on Tuesday, July 26th. The medical technology company reported $2.25 EPS for the quarter, missing analysts’ consensus estimates of $2.28 by ($0.03). Stryker had a return on equity of 23.34% and a net margin of 11.79%. During the same period in the prior year, the firm earned $2.25 earnings per share. On average, research analysts expect that Stryker Co. will post 9.38 earnings per share for the current year.

Stryker Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, October 31st. Investors of record on Friday, September 30th will be issued a $0.695 dividend. This represents a $2.78 annualized dividend and a yield of 1.26%. The ex-dividend date is Thursday, September 29th. Stryker’s dividend payout ratio is 51.20%.

Analyst Upgrades and Downgrades

SYK has been the subject of several analyst reports. BTIG Research reduced their price target on shares of Stryker from $244.00 to $238.00 and set a “buy” rating for the company in a research report on Tuesday, September 6th. Stifel Nicolaus lowered their price target on Stryker from $285.00 to $245.00 in a report on Monday, July 18th. Truist Financial increased their price objective on Stryker to $220.00 and gave the company an “outperform” rating in a research report on Wednesday, July 27th. Morgan Stanley decreased their target price on Stryker from $270.00 to $220.00 and set an “equal weight” rating for the company in a research report on Friday, July 15th. Finally, Cowen dropped their price target on shares of Stryker from $305.00 to $233.00 and set an “outperform” rating on the stock in a report on Friday, July 22nd. Four investment analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $256.29.

Stryker Company Profile

(Get Rating)

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. This segment also offers spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in spinal injury, deformity, and degenerative therapies.

Recommended Stories

Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Co. (NYSE:SYKGet Rating).

Institutional Ownership by Quarter for Stryker (NYSE:SYK)

Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.